Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval
Open Access
- 1 January 2024
- journal article
- review article
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (14) , e134
Abstract
Choi HS, et al. J Korean Med Sci. 2024 Apr;39(14):e134. https://doi.org/10.3346/jkms.2024.39.e134Keywords
This publication has 100 references indexed in Scilit:
- Amubarvimab/Romlusevimab: First ApprovalDrugs, 2022
- Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2—A narrative reviewJournal of Medical Virology, 2022
- Niclosamide for Covid-19: bridging the gapMolecular Biology Reports, 2021
- The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical studyInflammation Research, 2021
- A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock PatientsDrugs, 2021
- Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?BioDrugs, 2020
- Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case seriesBasic Research in Cardiology, 2020
- Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USADrugs & Therapy Perspectives, 2018
- Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathwaysMolecular Biology Reports, 2014
- Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s DiseaseDrugs & Aging, 2013